title: Vaccination and treatment trials against murine leishmaniasis with semi-purified Leishmania antigens.
abstract: Antigens with molecular weight ranges of 94-67 kDa (LiF2), 30-20 kDa (LiF5), or below 20 kDa (LiF6), isolated from lysates of Leishmania infantum promastigotes by electroelution from polyacrylamide gels were injected into mice which were genetically either partially resistant (C57BL/6) or susceptible (BALB/c) to Leishmania infection. One month after the completion of the intravenous (C57BL/6) or subcutaneous (BALB/c) schedules, the mice were challenged with 1 x 10(3) L. major promastigotes. All mice immunized with LiF2, LiF5 and LiF6 were completely resistant. Furthermore, the C57BL/6 mice immunized with LiF2 resisted a second challenge with 1 x 10(4) L. major amastigotes. 5 months later, LiF2 antigen was used for immunotherapy of L. major leishmaniasis; parasites disappeared from the treated skin lesions, although ensuing systemic infection could not be averted.
authors.affiliation: Laboratoire de Parasitologie Expérimentale, CHU Pitié-Salpétrière, Paris, France.
authors.forename: L
authors.initials: L
authors.lastname: Monjour
authors.forename: I
authors.initials: I
authors.lastname: Vouldoukis
authors.forename: B W
authors.initials: BW
authors.lastname: Ogunkolade
authors.forename: C
authors.initials: C
authors.lastname: Hetzel
authors.forename: M
authors.initials: M
authors.lastname: Ichen
authors.forename: D
authors.initials: D
authors.lastname: Frommel
mesh_terms: D000818:Animals; D000953:Antigens, Protozoan / Q000008:administration & dosage*; D005260:Female; D007114:Immunization; D007167:Immunotherapy; D007893:Leishmania donovani / Q000276:immunology*; D007898:Leishmaniasis, Visceral / Q000517:prevention & control* / Q000628:therapy; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL
chemical_list: D000953:Antigens, Protozoan